This taken from their website!
PROJECTED ROYALTY REVENUES
February 25, 1999
SYBD has recently prepared a complete package of pro forma financial
statements and projections for the three lead products – Oxycyteä ,
Fluoroventä , and the implanted glucose biosensor - currently under
development. From that package, we've attached for your information a
summary statement of projected royalty revenues for the five year period
following FDA approval. The complete package is available on request.
Royalty revenues are projected for the U.S. market only because solid U.S.
market research data are available. We have, however, projected global
revenues based on less adequate market data, and these projections are also
available on request.
These projections continue to support our firm belief that SYBD's lead
products can generate very significant returns for the company and its
shareholders. However, it must be realized that these are forward looking
statements that are subject to risks and uncertainties, as outlined in more
detail in the complete financial package and in SYBD's 10-K and 10-Q
filings.
SYNTHETIC BLOOD INTERNATIONAL, INC.
PROJECTED FINANCIAL STATEMENTS
SUPPLEMENTARY INFORMATION
PROJECTED REVENUE SUMMARY
DOMESTIC MARKET ONLY
YEAR AFTER FDA APPROVAL
YEAR 1
YEAR 2
YEAR 3
YEAR 4
YEAR 5
BIOSENSOR ROYALTY
REVENUE
$ 4,800,000
$ 9,600,000
$ 14,592,000
$ 19,920,000
$ 28,800,000
BLOOD TRANSFUSION
ROYALTY REVENUE
$ 7,200,000
$17,280,000
$ 34,560,000
$ 60,480,000
$ 93,600,000
OXYGEN THERAPEUTIC
ROYALTY REVENUE
$ 4,968,000
$ 9,315,000
$ 14,904,000
$ 21,735,000
$ 29,808,000
FLUOROVENT ROYALTY
REVENUE
$15,300,000
$30,600,000
$ 45,900,000
$ 61,200,000
$ 76,500,000
TOTAL PROJECTED PRODUCT
ROYALTY REVENUE
$32,268,000
$66,795,000
$109,956,000
$163,335,000
$ 228,708,000
Terry |
